TX-PANDA-POWER-FUNDS
20.12.2013 15:11:32 CET | Business Wire | Pressemeddelelse
Panda Power Funds today announced that it has completed the acquisition and successful financing of Moxie Energy’s planned 829-MW natural gas-fueled, combined-cycle “Patriot” generating station, located in Lycoming County, Pennsylvania. When completed, the Patriot project will be the second new power plant in the Keystone State — after Panda’s “Liberty” power plant — specifically developed to take advantage of its proximity to the Marcellus Shale. Panda will immediately start construction on the 85-acre site and expects commercial operations to begin by the middle of 2016.
Goldman Sachs, Credit Suisse, Ares Capital, Union Bank and Investec acted as joint lead arrangers for the senior debt financing of the plant. Panda Patriot raised debt capital totaling $651.5 million. Panda Liberty, financed in August of this year, raised debt capital totaling $627 million. The Patriot transaction marks the fifth financing of a large-scale power facility by Panda Power Funds in 17 months. The fund is supplying equity for the Patriot project along with a large institutional co-investor.
The Patriot project is Panda Power Fund’s second development acquisition from Moxie Energy in the PJM Interconnection.
“There’s no grass growing under our feet. I’m extremely proud of a Panda team that has closed five deals of this size in 17 months,” said Todd W. Carter, president and senior partner of Panda Power Funds. “I am also pleased to add another Pennsylvania project to our portfolio. Using natural gas from the Marcellus Shale, the Panda Patriot generating station will provide clean, low-cost power to Pennsylvanians for generations to come.
“Moxie Energy is to be commended for developing the right power generation projects in precisely the right place, at the right time.”
“Panda performs exhaustive due diligence, and when it’s time to act, they move quickly,” said Aaron Samson, chief executive officer of Moxie Energy. “We’ve enjoyed working with them through both acquisitions.”
The Panda Patriot project has been strategically sited on the Marcellus Shale, estimated to be the second largest natural gas field in the world. The Marcellus contains up to a projected 330 trillion cubic feet of recoverable natural gas, or the equivalent of 115 years of production at current levels. The Patriot project’s proximity to such a large supply of natural gas is expected to provide a significant operating cost advantage for the power plant.
The Patriot plant will utilize Siemens H-class gas turbines — the world’s first generation technology to achieve combined-cycle net operating efficiencies of greater than 60 percent. The two single shaft power trains will make the Patriot plant one of the cleanest, most efficient natural gas-fueled power plants in the United States. In addition, unlike approximately 95 percent of the nation’s generating facilities, the plant will be cooled with air rather than water. As a result, the Patriot plant will not draw water from, or discharge water into, the Western Branch of the Susquehanna River — eliminating potential impacts to species in the Susquehanna watershed.
The Patriot plant will make a significant economic contribution to the area during construction and the facility’s first 10 years of operation. Approximately 500 jobs will be created to construct the Patriot power plant at peak construction. During operations, the generating station will create an estimated 27 skilled jobs to operate the facility and 45 indirect jobs within the community to support the plant.
Gemma-Lane will serve as the project EPC Contractor and Siemens Energy Inc. will provide the power island package, including the gas turbines, steam turbines and heat recovery steam generators. Gemma-Lane will be responsible for installing the power island equipment and for the engineering, procurement and installation of the balance of the plant, and the commissioning of the facility. Construction will take approximately 30 months.
South Jersey Resources Group, a subsidiary of South Jersey Industries, Inc., is the contracted gas supplier for the plant.
The generating station will be located in Clinton Township in Lycoming County, approximately 125 miles northwest of Philadelphia, Pennsylvania. When completed, the generating station will be able to supply the power needs of up to 1 million homes in Pennsylvania.
About Panda Power Funds
Founded in 2010, Panda Power Funds is a private equity firm headquartered in Dallas, Texas, which has the ability to develop, acquire, construct, finance and operate large-scale, natural gas-fueled power generation facilities. Panda has five combined-cycle power plants currently under construction in Texas and Pennsylvania with a total capacity of nearly 4,000 megawatts and has announced a 750-MW combined-cycle power plant in Northern Virginia and an 859-MW power facility in Southern Maryland. The fund built a 20-megawatt solar farm in Southwest New Jersey that is one of the largest solar facilities in the Northeast United States. Additional information on Panda Power Funds can be found at www.pandafunds.com .
About The Siemens Energy Sector
The Siemens Energy Sector is the world's leading supplier of a broad spectrum of products, services and solutions for power generation in thermal power plants and using renewables, power transmission in grids and for the extraction, processing and transport of oil and gas. In fiscal 2013 (ended September 30), the Energy Sector had revenues of EUR26.6 billion and received new orders totaling approximately EUR28.8 billion and posted a profit of approximately EUR2 billion. On September 30, 2013, the Energy Sector had a work force of approximately 83,500. Further information is available at: www.siemens.com/energy .
About Moxie Energy
Moxie Energy, LLC is a private development firm formed in 2009, which has a demonstrated capability to develop large complex power generation projects. Additional information on Moxie Energy can be found at www.moxieenergy.com .
About Gemma-Lane:
Gemma-Lane brings together the strengths of two highly experienced construction organizations. Gemma Power Systems is a full service EPC contractor with the proven ability of designing, building and commissioning over 10,000 MW of large-scale clean gas-fired and renewable energy projects. Gemma Power Systems, LLC is a wholly owned subsidiary of Argan Inc. (NYSE: AGX) and is one of the largest power contractors in the Northeastern US. Currently ranked as 43rd on Engineering News-Record’s (ENR) ‘Top 400 Contractors’ list, The Lane Construction Corporation is one of America’s premier heavy civil contractors. With experience in the shale gas industry, Lane is committed to providing a responsible and comprehensive approach to develop America’s domestic energy resources. Additional information about Gemma-Lane Patriot Partners and its parent companies can be found at www.Gemma-Lane.com .
About South Jersey Resources Group
South Jersey Resources Group, a subsidiary of South Jersey Industries’ non-regulated businesses, markets natural gas storage, commodity and transportation assets on a wholesale basis in the mid-Atlantic, Appalachian and southern states.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20131220005172/en/
Contact:
Panda Power Funds
Bill Pentak, 972-361-2000
breakingnews@pandafunds.com
or
Siemens
AG
Christian S. Wilson, 49 9131 18-4974
christian_stuart.wilson@siemens.com
or
Claire
Hassett, 202-730-1012
claire.hassett@siemens.com
or
Moxie
Energy
Kent Morton, 855-446-6943
kmorton@moxieenergy.com
or
Gemma-Lane
Bill
Carter, 860-659-0509
WCarter@gemmapower.com
or
South
Jersey Resources Group
Joanne Brigandi, 609-561-9000 x4240
JBRIGANDI@sjindustries.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
